Dopamine receptors in human adipocytes: Expression and functions

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Borcherding, Dana C ^a   Hugo, Eric R ^a   Idelman, Gila ^a   de Silva, Anuradha ^a   Richtand, Nathan W ^a   Loftus, Jean ^b   Ben Jonathan, Nira ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CHRIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CEREBROSIDE SULFATASE; CYCLIC AMP; CYCLIC GMP; DOPAMINE RECEPTOR; INTERLEUKIN 6; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADIPOSE TISSUE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADIPOCYTES; ADIPOSE TISSUE; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; CEREBROSIDE-SULFATASE; CYCLIC AMP; CYCLIC GMP; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DOPAMINE;

EID: 80053148733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025537     Document Type: Article

References (56)

1. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG, (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
2. Neve KA, Seamans JK, Trantham-Davidson H, (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-205.
3. Sidhu A, Niznik HB, (2000) Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci 18: 669-677.
4. Lee MY, Heo JS, Han HJ, (2006) Dopamine regulates cell cycle regulatory proteins via cAMP, Ca(2+)/PKC, MAPKs, and NF-kappaB in mouse embryonic stem cells. J Cell Physiol 208: 399-406.
5. Chen J, Rusnak M, Luedtke RR, Sidhu A, (2004) D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem 279: 39317-39330.
6. White RE, Kryman JP, El-Mowafy AM, Han G, Carrier GO, (2000) cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BK(Ca) channel activity in coronary artery smooth muscle cells. Circ Res 86: 897-905.
7. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, et al. (2007) Novel insights in dopamine receptor physiology. Eur J Endocrinol 156 (Suppl 1): S13-S21.
8. Amenta F, Ricci A, Tayebati SK, Zaccheo D, (2002) The peripheral dopaminergic system: morphological analysis, functional and clinical applications. Ital J Anat Embryol 107: 145-167.
9. Ben-Jonathan N, Hnasko R, (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22: 724-763.
10. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW, (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17: 639-669.
11. Zinger M, McFarland M, Ben-Jonathan N, (2003) Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab 88: 689-696.
12. Brandebourg TD, Hugo ER, Ben-Jonathan N, (2007) Adipocyte prolactin: regulation of release and putative functions. Diabetes,Obesity and Metabolism 9: 364-377.
13. Hugo ER, Borcherding DC, Gersin KS, Loftus J, Ben-Jonathan N, (2008) Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes. J Clin Endocrinol Metab 93: 4006-4012.
14. Ben-Jonathan N, (1985) Dopamine: a prolactin-inhibiting hormone. Endocr Rev 6: 564-589.
15. Nisoli E, Tonello C, Memo M, Carruba MO, (1992) Biochemical and functional identification of a novel dopamine receptor subtype in rat brown adipose tissue. Its role in modulating sympathetic stimulation-induced thermogenesis. J Pharmacol Exp Ther 263: 823-829.
16. Goldstein DS, Eisenhofer G, Kopin IJ, (2003) Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 305: 800-811.
17. Goldstein DS, Swoboda KJ, Miles JM, Coppack SW, Aneman A, et al. (1999) Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab 84: 2523-2531.
18. Eisenhofer G, Coughtrie MW, Goldstein DS, (1999) Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol Suppl 26: S41-S53.
19. Eldrup E, (2004) Significance and origin of DOPA, DOPAC, and dopamine-sulphate in plasma, tissues and cerebrospinal fluid. Dan Med Bull 51: 34-62.
20. Strobel G, Werle E, Weicker H, (1990) Isomer specific kinetics of dopamine beta-hydroxylase and arylsulfatase towards catecholamine sulfates. Biochem Int 20: 343-351.
21. Ghosh D, (2007) Human sulfatases: a structural perspective to catalysis. Cell Mol Life Sci 64: 2013-2022.
22. Ahima RS, (2006) Adipose tissue as an endocrine organ. Obesity (Silver Spring) 14 (Suppl 5): 242S-249S.
23. Shetty S, Kusminski CM, Scherer PE, (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30: 234-239.
24. Fain JN, (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74: 443-477.
25. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, et al. (2001) beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86: 5864-5869.
26. Goossens GH, Jocken JW, van Baak MA, Jansen EH, Saris WH, et al. (2008) Short-term beta-adrenergic regulation of leptin, adiponectin and interleukin-6 secretion in vivo in lean and obese subjects. Diabetes Obes Metab 10: 1029-1038.
27. Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, et al. (2001) Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 86: 2281-2288.
28. Fain JN, Cowan GS Jr, Buffington C, Li J, Pouncey L, et al. (2000) Synergism between insulin and low concentrations of isoproterenol in the stimulation of leptin release by cultured human adipose tissue. Metabolism 49: 804-809.
29. Than A, Ye F, Xue R, Ong JW, Poh CL, et al. (2011) The crosstalks between adipokines and catecholamines. Mol Cell Endocrinol 332: 261-270.
30. Hugo ER, Brandebourg TD, Comstock CE, Gersin KS, Sussman JJ, et al. (2006) LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 147: 306-313.
31. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, et al. (2004) Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 64: 5551-5555.
32. Mignini F, Bronzetti E, Felici L, Ricci A, Sabbatini M, et al. (2000) Dopamine receptor immunohistochemistry in the rat choroid plexus. J Auton Pharmacol 20: 325-332.
33. Nair VD, Sealfon SC, (2003) Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor. J Biol Chem 278: 47053-47061.
34. Chang PL, Rosa NE, Davidson RG, (1981) Differential assay of arylsulfatase A and B activities: a sensitive method for cultured human cells. Anal Biochem 117: 382-389.
35. Lapensee CR, Hugo ER, Ben-Jonathan N, (2008) Insulin stimulates interleukin-6 expression and release in LS14 human adipocytes through multiple signaling pathways. Endocrinology 149: 5415-5422.
36. Maayan L, Vakhrusheva J, Correll CU, (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35: 1520-1530.
37. Ricci A, Bronzetti E, Mignini F, Tayebati SK, Zaccheo D, et al. (1999) Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96: 234-240.
38. Ricci A, Bronzetti E, Felici L, Tayebati SK, Amenta F, (1997) Dopamine D4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci Lett 229: 130-134.
39. Guest SJ, Hadcock JR, Watkins DC, Malbon CC, (1990) Beta 1- and beta 2-adrenergic receptor expression in differentiating 3T3-L1 cells. Independent regulation at the level of mRNA. J Biol Chem 265: 5370-5375.
40. Dixon TM, Daniel KW, Farmer SR, Collins S, (2001) CCAAT/enhancer-binding protein alpha is required for transcription of the beta 3-adrenergic receptor gene during adipogenesis. J Biol Chem 276: 722-728.
41. Strott CA, (2002) Sulfonation and molecular action. Endocr Rev 23: 703-732.
42. Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, et al. (1999) X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity. J Biol Chem 274: 37862-37868.
43. Valle LD, Toffolo V, Nardi A, Fiore C, Bernante P, et al. (2006) Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. J Endocrinol 190: 129-139.
44. Matzner U, Breiden B, Schwarzmann G, Yaghootfam A, Fluharty AL, et al. (2009) Saposin B-dependent reconstitution of arylsulfatase A activity in vitro and in cell culture models of metachromatic leukodystrophy. J Biol Chem 284: 9372-9381.
45. Biffi A, Cesani M, Fumagalli F, Del CU, Baldoli C, et al. (2008) Metachromatic leukodystrophy- mutation analysis provides further evidence of genotype-phenotype correlation. Clin Genet 74: 349-357.
46. Gieselmann V, (2008) Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr Suppl 97: 15-21.
47. Regis S, Corsolini F, Stroppiano M, Cusano R, Filocamo M, (2002) Contribution of arylsulfatase A mutations located on the same allele to enzyme activity reduction and metachromatic leukodystrophy severity. Hum Genet 110: 351-355.
48. Ben-Jonathan N, Munsick RA, (1980) Dopamine and prolactin in human pregnancy. J Clin Endocrinol Metab 51: 1019-1025.
49. Golander A, Barrett J, Hurley T, Barry S, Handwerger S, (1979) Failure of bromocriptine, dopamine, and thyrotropin-releasing hormone to affect prolactin secretion by human decidual tissue in vitro. J Clin Endocrinol Metab 49: 787-789.
50. Rondinone CM, (2006) Adipocyte-derived hormones, cytokines, and mediators. Endocrine 29: 81-90.
51. Maury E, Brichard SM, (2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 314: 1-16.
52. Zeigerer A, Rodeheffer MS, McGraw TE, Friedman JM, (2008) Insulin regulates leptin secretion from 3T3-L1 adipocytes by a PI 3 kinase independent mechanism. Exp Cell Res 314: 2249-2256.
53. Collins S, Surwit RS, (2001) The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog Horm Res 56: 309-328.
54. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, et al. (2007) Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32: 1715-1726.
55. Nasrallah HA, (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13: 27-35.
56. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T, (2003) Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37: 193-220.